CRANBURY, N.J. and SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the company has leased laboratory space for a focused, small scale research facility in San Diego. The facility will be used to support ongoing research into new applications of the company's platform technology.
"With proof of concept for pharmacological chaperones now established, research at the San Diego facility will support Amicus' efforts to expand our early stage pipeline," said David Lockhart, Ph.D., chief scientific officer for Amicus Therapeutics. "Locating the new laboratory in San Diego allows us to complement and expand our existing research capabilities in Cranbury by tapping into the significant resources and expertise of the San Diego science and biotechnology community."
"We believe pharmacological chaperones have significant potential to treat a broad range of genetic diseases," added John Crowley, president and CEO of Amicus. "The focus of our research efforts in San Diego will be to assess new chaperone applications in diseases with high unmet medical needs and larger patient populations particularly in the areas of neurodegenerative and metabolic disorders. This small scale facility will complement our core research and development activities in New Jersey."
The new laboratory space was included in Amicus' operating plan and budget for 2008 as part of increased investment in research beyond the lysosomal storage disorders. Amicus expects to begin occupying the space immediately.
About Amicus Therapeutics
|SOURCE Amicus Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved